Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes

British Journal of Pharmacology

Volumn 158, Issue 7, 2009, Pages 1848-1856

  Mantovani, M ^a   Dooley, D J ^b   Weyerbrock, A ^a   Jackisch, R ^a   Feuerstein, T J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b IDSC   (United States)

Author keywords

(S,S) reboxetine; 5 hydroxytryptamine uptake; Atomoxetine; Citalopram; Desipramine; Duloxetine; Fluoxetine; Fluvoxamine; Milnacipran; Neocortex; Noradrenaline uptake; Synaptosomes

Indexed keywords

ATOMOXETINE; CITALOPRAM; DESIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRITIUM;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CHILD; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEOCORTEX; NONHUMAN; PRIORITY JOURNAL; RAT; SCHOOL CHILD; SPECIES DIFFERENCE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ANIMALS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOCORTEX; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RATS; RATS, WISTAR; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SPECIES SPECIFICITY; SYNAPTOSOMES; YOUNG ADULT;

EID: 71249139888     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00478.x     Document Type: Article

References (43)

1. Barker EL, Blakely RD (1996). Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol 50 : 957 965.
2. Barker EL, Kimmel HL, Blakely RD (1994). Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol Pharmacol 46 : 799 807.
3. Beique JC, Lavoie N, de Montigny C, Debonnel G (1998). Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 349 : 129 132.
4. Berton O, Nestler EJ (2006). New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7 : 137 151.
5. Blakely RD, Berson HE, Fremeau RT Jr., Caron MG, Peek MM, Prince HK et al. (1991). Cloning and expression of a functional serotonin transporter from rat brain. Nature 354 : 66 70.
6. Bruss M, Porzgen P, Bryan-Lluka LJ, Bönisch H (1997). The rat norepinephrine transporter: Molecular cloning from PC12 cells and functional expression. Brain Res Mol Brain Res 52 : 257 262.
7. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL et al. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25 : 871 880.
8. Chalon S, Hall H, Saba W, Garreau L, Dollé F, Halldin C et al. (2006). Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta- carbomethoxy-3beta-(4′-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. J Pharmacol Exp Ther 317 : 147 152.
9. 50) of an enzymatic reaction. Biochem Pharmacol 22 : 3099 3108.
10. Feuerstein TJ (2007). Presynaptic receptors for dopamine, histamine and serotonin. Handb Exp Pharmacol 2008 : 289 338.
11. Feuerstein TJ, Limberger N (1999). Mathematical analysis of the control of neurotransmitter release by presynaptic receptors as a supplement to experimental data. Naunyn Schmiedebergs Arch Pharmacol 359 : 345 359.
12. Feuerstein TJ, Sauermann W (2005). What is the opposite of a receptor reserve? Int J Pharmacol 1 : 195 202.
13. Feuerstein TJ, Hertting G, Lupp A, Neufang B (1986). False labelling of dopaminergic terminals in the rabbit caudate nucleus: uptake and release of [3H]-5-hydroxytryptamine. Br J Pharmacol 88 : 677 684.
14. Frazer A (2001). Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies. J Clin Psychiatry 62 (Suppl. 12 16 23.
15. Gardner MJ, Altman DG (1986). Confidence intervals rather than P values: Estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 292 : 746 750.
16. Gehlert DR, Schober DA, Gackenheimer SL (1995). Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain. J Neurochem 64 : 2792 2800.
17. Göthert M, Schlicker E (1997). Regulation of 5-HT release in the CNS by presynaptic 5-HT autoreceptors and by 5-HT heteroreceptors. In : Baumgarten HG, Göthert M (eds). Serotonergic Neurons and 5-HT Receptors in the CNS. Springer : Berlin, Heidelberg and New York, pp. 307 350.
18. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH (2004). The selective norepinephrine reuptake inhibitor antidepressant reboxetine: Pharmacological and clinical profile. CNS Drug Rev 10 : 23 44.
19. 3H]5-hydroxytryptamine in slices of human and rat cortical brain tissue. Brain Res 275 : 99 104.
20. Hyttel J (1994). Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9 (Suppl. 1 19 26.
21. Jeannotte AM, Sidhu A (2008). Regulated interactions of the norepineprhine transporter by the actin and microtubule cytoskeletons. J Neurochem 105 : 1668 1682.
22. Kasamo K, Blier P, de Montigny C (1996). Blockade of the serotonin and norepinephrine uptake processes by duloxetine: In vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther 277 : 278 286.
23. 3H]imipramine binding in rat hypothalamus: Association with uptake of serotonin but not of norepinephrine. Science 210 : 1133 1135.
24. Lieb K, Fiebich BL, Herpfer I, Mantovani M, Löffler M, Feuerstein TJ (2005). No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. Eur Neuropsychopharmacol 15 : 641 646.
25. Löffler M, Bubl B, Huethe F, Hubbe U, McIntosh JM, Jackisch R et al. (2006). Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release. Brain Res Bull 68 : 361 373.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193 : 265 275.
27. Lupp A, Bär KI, Lücking CH, Feuerstein TJ (1992). Different effects of serotonin (5-HT) uptake blockers in caudate nucleus and hippocampus of the rabbit: Role of monoamine oxidase in dopaminergic terminals. Psychopharmacology 106 : 118 126.
28. 3H]hydroxytryptamine uptake in rat diencephalon. J Neurochem 59 : 1856 1861.
29. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283 : 1305 1322.
30. Pacholczyk T, Blakely RD, Amara SG (1991). Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350 : 350 354.
31. 3H]citalopram binding to brain and platelet membranes of human and rat. J Neurochem 56 : 248 252.
32. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS et al. (1993). Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 90 : 2542 2546.
33. Richelson E, Pfenning M (1984). Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104 : 277 286.
34. Ruhé HG, Mason NS, Schene AH (2007). Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: A meta-analysis of monoamine depletion studies. Mol Psychiatry 12 : 331 359.
35. Sanchez C, Hyttel J (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19 : 467 489.
36. Stahl SM, Grady MM, Moret C, Briley M (2005). SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10 : 732 747.
37. Steffens M, Feuerstein TJ (2004). Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex - involvement of Na(+)/K(+)-ATPase. Neurochem Int 44 : 529 538.
38. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ (2004). Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 55 : 320 322.
39. Wheeler DD, Edwards AM, Ondo JG (1993). Dopamine uptake in five structures of the brain: comparison of rate, sodium dependence and sensitivity to cocaine. Neuropharmacol 32 : 501 508.
40. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW (1993). LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8 : 23 33.
41. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP et al. (2000). Reboxetine: A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47 : 818 829.
42. 3H]imipramine. II. The role of sodium ions. Neuropharmacology 26 : 1081 1085.
43. Zhou J (2004). Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future 29 : 1235 1244.